title: Perioperative chemotherapy for resectable colorectal hepatic metastases-What does the EORTC 40983 trial update mean?
abstract: The liver is the most common site of colorectal cancer metastasis. Although successful resection leads to durable overall survival (OS), local and distant recurrence is common. As a result, multidisciplinary strategies have been developed to decrease recurrence rates as well as increase the number of candidates for resection. A recent update to the European Organisation for Research and Treatment of Cancer (EORTC) Intergroup trial 40983 has been published comparing perioperative chemotherapy to surgery alone. This randomized trial initially demonstrated a benefit in progression free survival (PFS) with the administration of perioperative FOLFOX chemotherapy, albeit with an increased rate of complications. Although this led many investigators and clinicians to adopt the perioperative approach, the recent update failed to report any advantage in OS and therefore results in further controversy as to the role of perioperative systemic chemotherapy in the treatment of resectable colorectal hepatic metastases.
authors.affiliation: Division of Surgical Oncology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
authors.forename: Chandrasekhar
authors.initials: C
authors.lastname: Padmanabhan
authors.affiliation: Division of Surgical Oncology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
authors.forename: Alexander
authors.initials: A
authors.lastname: Parikh
keywords: Chemotherapy; colorectal neoplasms; liver neoplasms; neoplasm metastases